Loading...
hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA
Aughton, K. Elander, N. O. Evans, A. Jackson, R. Campbell, F. Costello, E. Halloran, C. M. Mackey, J. R. Scarfe, A. G.
Aughton, K.
Elander, N. O.
Evans, A.
Jackson, R.
Campbell, F.
Costello, E.
Halloran, C. M.
Mackey, J. R.
Scarfe, A. G.
Citations
Altmetric:
Abstract
Authors
Aughton, K.
Elander, N. O.
Evans, A.
Jackson, R.
Campbell, F.
Costello, E.
Halloran, C. M.
Mackey, J. R.
Scarfe, A. G.
Valle, Juan W
Carter, R.
Cunningham, D.
Tebbutt, N. C.
Goldstein, D.
Shannon, J.
Glimelius, B.
Hackert, T.
Charnley, R. M.
Anthoney, A.
Lerch, M. M.
Mayerle, J.
Palmer, D. H.
Buchler, M. W.
Ghaneh, P.
Neoptolemos, J. P.
Greenhalf, W.
Elander, N. O.
Evans, A.
Jackson, R.
Campbell, F.
Costello, E.
Halloran, C. M.
Mackey, J. R.
Scarfe, A. G.
Valle, Juan W
Carter, R.
Cunningham, D.
Tebbutt, N. C.
Goldstein, D.
Shannon, J.
Glimelius, B.
Hackert, T.
Charnley, R. M.
Anthoney, A.
Lerch, M. M.
Mayerle, J.
Palmer, D. H.
Buchler, M. W.
Ghaneh, P.
Neoptolemos, J. P.
Greenhalf, W.
Description
Date
2021
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 1.79 MB
Keywords
Type
Article
Citation
Aughton K, Elander NO, Evans A, Jackson R, Campbell F, Costello E, et al. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA Vol. 13, Cancers. MDPI AG; 2021. p. 5758.